EASTHAM KARIN 4

What Happened

• Karin Eastham, a director of Veracyte, sold a total of 3,729 shares in two open-market transactions on June 18, 2026, generating aggregate proceeds of approximately $197,234. The first sale was 3,200 shares at a weighted average price reported as $52.78 for $168,906; the second was 529 shares at a weighted average price reported as $53.55 for $28,328. These were sales (not purchases) and therefore are routine dispositions rather than direct bullish signals.

Key Details

• Transaction dates and prices:
  • 2026-06-18: 3,200 shares sold, weighted avg price $52.78 (sale price range reported 52.26–53.26) — proceeds $168,906. (F2)
  • 2026-06-18: 529 shares sold, weighted avg price $53.55 (sale price range reported 53.29–53.70) — proceeds $28,328. (F3)
• Aggregate proceeds: ~$197,234.
• Footnotes: Transactions were executed under a Rule 10b5-1 trading plan adopted by Ms. Eastham on September 5, 2025 (F1). Detailed per-price share breakdown is available to the SEC, issuer, or shareholders on request (F2, F3).
• Shares owned after the transactions: not disclosed in the provided filing excerpt.
• Filing: Report filed 2026-06-22 reporting 2026-06-18 trades (timeliness not indicated in the provided data).

Context

• These trades were executed under a pre-established 10b5-1 plan, which is a common mechanism that allows insiders to sell shares according to a preset schedule. Sales under such plans are generally treated as pre-arranged and not necessarily reflective of immediate sentiment. Purchases typically carry more weight for interpreting insider confidence; this filing documents routine sales.